Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 9, 2014

Primary Completion Date

March 30, 2017

Study Completion Date

January 19, 2018

Conditions
Lupus Nephritis
Interventions
DRUG

Ixazomib

Ixazomib capsules.

DRUG

Placebo

Ixazomib placebo-matching capsules.

Trial Locations (35)

Unknown

La Jolla

Upland

Port Charlotte

Evergreen Park

Brooklyn

Great Neck

Manhasset

New York

Middleburg Heights

Lancaster

Charleston

Jackson

Lille

Amiens

Paris

Strasbourg

Frankfurt am Main

Aachen

Düsseldorf

Mainz

Berlin

Essen

Freiburg im Breisgau

Rome

Turin

Pisa

Padua

Kazan'

Kemerovo

Saint Petersburg

Madrid

Bilbao

Madrid

London

London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02176486 - Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) | Biotech Hunter | Biotech Hunter